Go to deals
Healthcare

St. Claraspital AG has been acquired by University Hospital Basel

University Hospital Basel (USB) has acquired St. Claraspital AG, expanding its network of specialized care and integrated services. With St. Claraspital’s strong community presence, expertise in acute and rehabilitation medicine and established outpatient clinics, this merger enhances USB’s ability to provide seamless, patient-centered treatment across the continuum of care.

St. Claraspital is a leading, systemically relevant hospital in Northwestern Switzerland, delivering high-quality care ranging from primary care services to highly complex treatments, with a particular focus on tumor and abdominal care. A round-the-clock emergency department and intensive care unit, supported by specialized, adjacent and diagnostic disciplines, ensure seamless and integrated patient care.

USB is one of Switzerland’s leading university hospitals and the largest healthcare center in Northwestern Switzerland. Founded in 1460 as part of the University of Basel’s Faculty of Medicine, USB now employs around 8,000 staff members, operates more than 700 beds and treats approximately 40,000 inpatients each year. Comprising 12 medical centers, USB offers comprehensive care across all medical specialties and collaborates closely with the University of Basel and leading life sciences companies.

Oaklins’ team in Switzerland acted as the lead advisor to the seller throughout the sales process, including preparation and approach, due diligence and parallel negotiations with potential buyers.

Parties
“I experienced the Oaklins Swiss team as a highly professional partner with outstanding transaction expertise. Throughout the engagement, collaboration took place at the senior level — built on trust, focus and mutual respect. The experienced team executed the ambitious timeline with great commitment, managing the process both efficiently and in a structured manner. This enabled us to select the very best new owner for St. Claraspital from several attractive options — an outcome that met the seller’s expectations in every respect.”

Raymond Cron

Chairman of the Board, St. Claraspital AG

Talk to the deal team

David Zürrer

Partner
Basel, Switzerland
Oaklins Switzerland

Jens Rutten

Partner
Zurich, Switzerland
Oaklins Switzerland

Florian Mattern

Senior Associate
Zurich, Switzerland
Oaklins Switzerland

Moritz Henniger

Analyst
Basel, Switzerland
Oaklins Switzerland

Related deals

Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
Healthcare

Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland

LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.

Learn more
EuroHospital Varna has been acquired by Intermedica Group
Healthcare

EuroHospital Varna has been acquired by Intermedica Group

EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.

Learn more
Olyos Group has acquired a controlling stake in NewScience
Healthcare

Olyos Group has acquired a controlling stake in NewScience

Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.

Learn more